newsfilter
← Latest News
GlobeNewswire·

Sigilon Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights

Company expects to complete its investigation of the clinical hold on its Phase 1/2 trial of SIG-001 in hemophilia A by year-end On track to initiate a Phase 1/2 trial of SIG-005 for MPS-1 in the fourth quarter of 2021 Company appoin